Stockreport

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Pharmaceuticals, Inc.  (SNDX) 
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.syndax.com
PDF – Topline data expected in 4Q24 could support sNDA filing in 1H25 –– Revumenib has the potential to address $2 billion mNPM1 and KMT2Ar R/R acute leukemia U.S. market op [Read more]